Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
1,899,381
-
Shares change
-
-315,560
-
Total reported value, excl. options
-
$122,176,472
-
Value change
-
-$19,204,656
-
Number of buys
-
8
-
Number of sells
-
-27
-
Price
-
$64.34
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q3 2018
51 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q3 2018.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,899,381 shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (800,128 shares), MEITAV DASH INVESTMENTS LTD (482,279 shares), CITIGROUP INC (200,337 shares), RAYMOND JAMES & ASSOCIATES (89,214 shares), BANK OF AMERICA CORP /DE/ (76,248 shares), SG Americas Securities, LLC (50,000 shares), MORGAN STANLEY (29,825 shares), CITADEL ADVISORS LLC (23,535 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (21,708 shares), and UBS Group AG (17,787 shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.